Newark, New Castle, USA, May 24, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global dostarlimab-gxly market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 15.6% during the forecast period 2023-2031.
Analysis of the global market for dostarlimab-gxly indicates that the revenue share is likely to rise significantly during the forecast period. A monoclonal antibody drug called dostarlimab-gxly, also marketed under the name Jemperli, is used to treat certain cancers.
Key Takeaways:
- The increasing number of patients with advanced or endometrial cancer is driving the market revenue share.
- Regulatory approvals allow for market entry and increased accessibility to patients.
- With the drug's approval, a large unmet medical need is now being addressed, which will help the dostarlimab-gxly market develop more broadly.
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/dostarlimabgxly-market/9033
Dostarlimab-gxly Market Scope
| Report Attribute | Details |
| CAGR | 15.6% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023 to 2031 |
| Historical Year | 2021 |
| Segments Covered | Cancer Type, End User, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Recent Development in the Dostarlimab-gxly Market:
- In February 2023, for adult patients with mismatch repair-deficient (dMMR), recurrent, or advanced endometrial cancer who have advanced on or after a previous platinum-containing treatment in any context and who are not candidates for radiation or curative surgery, the FDA has approved dostarlimab-gxly (Jemperli). The phase 1 GARNET study's data supported the customary approval.
Competitive Landscape
The company operating in the global market for dostarlimab-gxly is:
• GSK Plc
Market Drivers and Restraints:
The global dostarlimab-gxly market revenue is driven by the rising incidences of cancer, increasing investments in R&D activities, and the government's initiatives in developing cancer therapeutics.
However, due to the price, reimbursement, and side effects, the dostarlimab-gxly market revenue growth is expected to be restrained.
Market Segmentation:
- Based on cancer type, the global dostarlimab-gxly market is segmented into endometrial cancer, skin cancer, lung cancer, liver cancer, kidney cancer, and others.
- Based on end users, the global dostarlimab-gxly market is segmented into hospitals, homecare settings, ambulatory surgical centers, and others.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/dostarlimab-gxly-market/9033
Segmentation By End User
Based on end-user, the hospital segment accounts for the highest revenue share in the global dostarlimab-gxly market due to the rising prevalence of endometrial cancer and the availability of the necessary infrastructure. Furthermore, these facilities are equipped with the knowledge and tools necessary to identify, manage, and treat cancer patients, including those who could benefit from dostarlimab-gxly, contributing to the segment's revenue share.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global dostarlimab-gxly market. This large revenue share is attributed to because of the increased incidence of cancer, the developed healthcare system, the high cost of healthcare, and the favorable reimbursement conditions.
Report Coverage
Growth Plus Reports carried out extensive market research on the dostarlimab-gxly market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- Reimbursement Scenarios
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL DOSTARLIMAB-GXLY MARKET- ANALYSIS & FORECAST, BY CANCER TYPE
- Endometrial Cancer
- Skin Cancer
- Lung Cancer
- Liver Cancer
- Kidney Cancer
- Others
- GLOBAL DOSTARLIMAB-GXLY MARKET- ANALYSIS & FORECAST, BY END USER
- Hospital
- Homecare Settings
- Ambulatory Surgical Centers
- Others
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-9033
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Opioid Induced Constipation Treatment Market by Drug Class (Laxatives, Peripherally Acting μ-opioid Receptor Antagonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Lithotripsy Devices Market by Type (Extracorporeal Shock Wave Lithotripsy Devices, Intracorporeal Lithotripsy Devices), Application (Kidney Stones, Ureteral Stones), End User (Hospitals, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031
Veterinary Auto-Immune Disease Diagnostics Market by Test Type (DNA Amplification Test, Biopsy Test), Indication (Canine Lupus, Pemphigus Disease), End User (Veterinary Hospital, Veterinary Clinics) – Global Outlook & Forecast 2023-2031
Cranial and Facial Implants Market by Type (Cranial, Facial), Material (Polymethyl Methacrylate, Porous Polyethylene) – Global Outlook & Forecast 2023-2031
Intervertebral Implants Market by Тype (Lumbar, Cervical), Material (Titanium, PEEK) – Global Outlook & Forecast 2023-2031
Unleashing the Power of Innovation in Med Tech https://growthplusmedtechroundup.com/
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
Unleashing the Power of Innovation in Med Tech
